IL17RA

interleukin 17 receptor A, the group of CD molecules|Interleukin receptors

Basic information

Region (hg38): 22:17084954-17115693

Previous symbols: [ "IL17R" ]

Links

ENSG00000177663NCBI:23765OMIM:605461HGNC:5985Uniprot:Q96F46AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • immunodeficiency 51 (Limited), mode of inheritance: AR
  • chronic mucocutaneous candidiasis (Supportive), mode of inheritance: AD
  • immunodeficiency 51 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Immunodeficiency 51ARAllergy/Immunology/InfectiousIndividuals have been described as susceptible to infections such as Candida albicans, Staphlycoccal skin infections, and bacterial respiratory infections, and awareness may allow early detection and early and aggressive treatment of infectionsAllergy/Immunology/Infectious21350122; 27930337

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the IL17RA gene.

  • Immunodeficiency_51 (698 variants)
  • not_specified (169 variants)
  • not_provided (38 variants)
  • IL17RA-related_disorder (16 variants)
  • Familial_Candidiasis,_Recessive (7 variants)
  • See_cases (2 variants)
  • Psoriasis (1 variants)
  • Chronic_mucocutaneous_candidiasis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the IL17RA gene is commonly pathogenic or not. These statistics are base on transcript: NM_000014339.7. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
10
clinvar
217
clinvar
6
clinvar
233
missense
1
clinvar
1
clinvar
365
clinvar
33
clinvar
5
clinvar
405
nonsense
5
clinvar
1
clinvar
4
clinvar
10
start loss
0
frameshift
11
clinvar
3
clinvar
6
clinvar
20
splice donor/acceptor (+/-2bp)
5
clinvar
5
Total 17 10 385 250 11

Highest pathogenic variant AF is 0.000013140259

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
IL17RAprotein_codingprotein_codingENST00000319363 1330740
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0003560.9991257180301257480.000119
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.7955625111.100.00003575559
Missense in Polyphen133144.260.921951854
Synonymous-1.942752371.160.00001871778
Loss of Function3.081128.80.3820.00000143305

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003310.000326
Ashkenazi Jewish0.000.00
East Asian0.00005580.0000544
Finnish0.000.00
European (Non-Finnish)0.0001420.000141
Middle Eastern0.00005580.0000544
South Asian0.00006530.0000653
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for IL17A (PubMed:17911633, PubMed:9367539). Receptor for IL17F (PubMed:19838198, PubMed:17911633). Binds to IL17A with higher affinity than to IL17F (PubMed:17911633). Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC (PubMed:16785495). Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC (PubMed:18684971). Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848). Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6 (PubMed:16785495, PubMed:17911633, PubMed:18684971). {ECO:0000269|PubMed:16785495, ECO:0000269|PubMed:17911633, ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:19838198, ECO:0000269|PubMed:21993848, ECO:0000269|PubMed:9367539}.;
Disease
DISEASE: Immunodeficiency 51 (IMD51) [MIM:613953]: A primary immunodeficiency disorder with altered immune responses and impaired clearance of fungal infections, selective against Candida. It is characterized by persistent and/or recurrent infections of the skin, nails and mucous membranes caused by organisms of the genus Candida, mainly Candida albicans. {ECO:0000269|PubMed:21350122}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
IL-17 signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);IL17 signaling pathway;JAK STAT MolecularVariation 1;JAK STAT MolecularVariation 2;JAK STAT pathway and regulation (Consensus)

Recessive Scores

pRec
0.203

Intolerance Scores

loftool
0.624
rvis_EVS
0.25
rvis_percentile_EVS
69.66

Haploinsufficiency Scores

pHI
0.118
hipred
N
hipred_score
0.270
ghis
0.516

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.941

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Il17ra
Phenotype
hematopoietic system phenotype; neoplasm; respiratory system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
cell surface receptor signaling pathway;positive regulation of interleukin-23 production;defense response to fungus;granulocyte chemotaxis;fibroblast activation;interleukin-17-mediated signaling pathway;positive regulation of cytokine production involved in inflammatory response;positive regulation of interleukin-5 secretion;positive regulation of interleukin-13 secretion
Cellular component
extracellular region;plasma membrane;integral component of plasma membrane
Molecular function
signaling receptor binding;protein binding;interleukin-17 receptor activity